[{"id":"a34627fb-07cd-4e73-aca5-cc7aa8e157f6","acronym":"PIQHASSO","url":"https://clinicaltrials.gov/study/NCT02723877","created_at":"2021-01-18T13:19:42.721Z","updated_at":"2024-07-02T16:37:01.374Z","phase":"Phase 1/2","brief_title":"PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)","source_id_and_acronym":"NCT02723877 - PIQHASSO","lead_sponsor":"PIQUR Therapeutics AG","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • bimiralisib (PQR309)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-03-22"},{"id":"f3d0a3de-f957-46f8-aa4d-0a7397be462c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02483858","created_at":"2021-01-18T11:57:53.238Z","updated_at":"2024-07-02T16:37:01.382Z","phase":"Phase 1","brief_title":"Study of Oral PQR309 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02483858","lead_sponsor":"PIQUR Therapeutics AG","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bimiralisib (PQR309)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 03/21/2019","study_completion_date":" 03/21/2019","last_update_posted":"2019-03-22"}]